Quick Answer
Enliven Therapeutics, Inc. reported Net Income Loss of -$103.69 million for the year ending 2025.
- Enliven Therapeutics, Inc. showed a decrease of -16.5% in Net Income Loss from 2024 to 2025.
- This data is from Enliven Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$4.19 million | Q2 2019: -$5.40 million | Q3 2019: -$6.62 million | Q1 2020: -$7.22 million | Q2 2020: -$10.20 million | Q3 2020: -$12.42 million | Q1 2021: -$10.26 million | Q2 2021: -$13.16 million | Q3 2021: -$13.65 million | Q1 2022: -$8.67 million | Q2 2022: -$8.89 million | Q3 2022: -$10.55 million | Q1 2023: -$14.72 million | Q2 2023: -$16.72 million | Q3 2023: -$20.77 million | Q1 2024: -$22.74 million | Q2 2024: -$19.95 million | Q3 2024: -$23.16 million | Q1 2025: -$28.54 million | Q2 2025: -$25.34 million | Q3 2025: -$20.15 million.
- Over the full 7 years of available data (2019 to 2025), Enliven Therapeutics, Inc.'s Net Income Loss has declined by 341.9%.
- Historical annual values: Fiscal year 2025: -$103.69 million | Fiscal year 2024: -$89.02 million | Fiscal year 2023: -$71.58 million | Fiscal year 2022: -$37.66 million | Fiscal year 2021: -$51.38 million | Fiscal year 2020: -$41.36 million | Fiscal year 2019: -$23.46 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: